Enliven Therapeutics, Inc.
ELVNNasdaqCIK 1672619HealthcareFiscal year ends Dec 31
Reports and events: 116 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1416:39 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-421761 |
| 2026-08-0516:15 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-335155 |
| 2026-08-0516:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335101 |
| 2026-06-2419:15 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000947871-26-000651 |
| 2026-06-1719:41 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000947871-26-000636 |
| 2026-06-1216:55 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-269635 |
| 2026-06-1108:09 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-266731 |
| 2026-06-1017:32 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-264085 |
| 2026-05-0716:17 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-211982 |
| 2026-05-0716:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211921 |
| 2026-04-2716:06 ET | DEF 14A | Proxy statementPeriod 2026-06-09 | 0001193125-26-182045 |
| 2026-03-0316:15 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-088232 |
| 2026-03-0316:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-088195 |
| 2026-01-0709:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-005535 |
| 2025-12-1109:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-315196 |
| 2025-11-1321:58 ET | 8-K/A | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-278466 |
| 2025-11-1216:15 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-277619 |
| 2025-11-1216:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277580 |
| 2025-08-1316:17 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001193125-25-179845 |
| 2025-08-1316:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-179837 |
| 2025-06-2516:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-146874 |
| 2025-06-1717:30 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000947871-25-000616 |
| 2025-06-1606:44 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-141085 |
| 2025-06-1306:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-140285 |
| 2025-05-1416:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-071412 |
| 2025-05-1416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-071387 |
| 2025-04-2816:05 ET | DEF 14A | Proxy statementPeriod 2025-06-24 | 0001193125-25-100456 |
| 2025-03-1316:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-038758 |
| 2025-03-1316:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-038737 |
| 2024-11-1316:15 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-126332 |
| 2024-11-1316:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126323 |
| 2024-08-1316:15 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-096239 |
| 2024-08-1316:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096204 |
| 2024-07-2918:12 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-083627 |
| 2024-06-1817:12 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-163507 |
| 2024-05-2916:06 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0001193125-24-149141 |
| 2024-05-2016:55 ET | SC 13D/A | Ownership report, active investor, amended | 0000947871-24-000499 |
| 2024-05-1416:15 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059573 |
| 2024-05-1416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059544 |
| 2024-04-2616:05 ET | DEF 14A | Proxy statementPeriod 2024-06-18 | 0001193125-24-117969 |
| 2024-04-1519:21 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-047395 |
| 2024-04-1108:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-092522 |
| 2024-04-0916:14 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-090821 |
| 2024-04-0416:39 ET | SC 13D/A | Ownership report, active investor, amended | 0000947871-24-000350 |
| 2024-03-1908:46 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-070839 |
| 2024-03-1416:15 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-031495 |
| 2024-03-1416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-031482 |
| 2024-02-1616:15 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-024915 |
| 2024-02-0216:15 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-010043 |
| 2023-11-0916:15 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062080 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:28 ET. Listed shows no prices and gives no investment advice.